Leerink sees surge in home dialysis; Vensana, LRV detail deal in CardioDx start-up Cleerly Health
This week we’ll focus on investor insights.
First, we’ll talk with Danielle Antalffy, managing director at SVB Leerink. Antalffy covers most of the major medtechs but we’ll focus on a new report she issues on sugaring home-based dialysis business.
What does this mean for Outset specifically? More broadly, do other medtechs need to build out their at-home/connectivity function?
Also, what does NeuroPace’s success mean for other medtech companies.
In a follow up to our interview with Dr. James Min, CEO of Cleerly Health, we talk with two venture investors in the early heart attack risk detection company.
Justin Klein, MD, of Vensana Capital walks us through the steps he took before leading the company’s recent $43 million Series B round.
Tripp Peake of LRV Health explains why the company interests his venture firm’s limited partner base.
This is an opportunity for entrepreneurs to better understand the venture capital due diligence process.
Chris Newmarker, executive editor of life sciences, delivers his Newmarker’s Newsmakers brings top news from Conformis, Stryker, Siemens Healthineers, Abbott, Medtronic and Levita Magnetics.